KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrana Health (ASTH) Gains from Investment Securities (2016 - 2025)

Astrana Health's Gains from Investment Securities history spans 10 years, with the latest figure at $7.6 million for Q3 2025.

  • For Q3 2025, Gains from Investment Securities rose 1851.66% year-over-year to $7.6 million; the TTM value through Sep 2025 reached $15.7 million, down 45.42%, while the annual FY2024 figure was $14.1 million, N/A changed from the prior year.
  • Gains from Investment Securities for Q3 2025 was $7.6 million at Astrana Health, up from -$7.8 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $24.8 million in Q4 2023 and bottomed at -$7.8 million in Q2 2025.
  • The 5-year median for Gains from Investment Securities is $358000.0 (2023), against an average of $3.7 million.
  • The largest annual shift saw Gains from Investment Securities plummeted 1574.07% in 2022 before it soared 1851.66% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $13.6 million in 2021, then crashed by 102.92% to -$398000.0 in 2022, then skyrocketed by 6330.9% to $24.8 million in 2023, then plummeted by 59.1% to $10.1 million in 2024, then decreased by 24.76% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for ASTH's Gains from Investment Securities are $7.6 million (Q3 2025), -$7.8 million (Q2 2025), and $5.7 million (Q1 2025).